Question 1

What is BioMarin Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax?

Accepted Answer

BioMarin Pharmaceuticals (BMRN) reported unrealized gain (loss), foreign currency transaction, before tax of -$6.71M in Q1 2026.

Question 2

How has BioMarin Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax changed year-over-year?

Accepted Answer

BioMarin Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax decreased by 166.9% year-over-year, from $10.03M to -$6.71M.

Question 3

What is the long-term trend for BioMarin Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax?

Accepted Answer

Over 2 years (2021 to 2025), BioMarin Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax has grown at a 57.0% compound annual growth rate (CAGR), from $1.81M to -$4.46M.

Question 4

What does unrealized gain (loss), foreign currency transaction, before tax mean?

Accepted Answer

Non-cash gains or losses from changes in currency exchange rates.

Question 5

How do you interpret unrealized gain (loss), foreign currency transaction, before tax?

Accepted Answer

High volatility indicates significant international exposure and sensitivity to global currency markets.

Question 6

How does unrealized gain (loss), foreign currency transaction, before tax compare across companies?

Accepted Answer

Common for multinational firms with global sales and supply chains.

BioMarin Pharmaceuticals BMRN Unrealized Gain (Loss), Foreign Currency Transaction, before Tax

Unrealized Gain (Loss), Foreign Currency Transaction, before Tax at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

Ask your AI about BioMarin Pharmaceuticals's unrealized gain (loss), foreign currency transaction, before tax.

Questions, answered.